{"entity":{"id":"paper-checkmate-141-ferris-nejm-2016","kind":"paper","name":"CheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum","aka":[],"tldr":"Nivolumab lengthened survival compared with standard single-agent chemotherapy in head and neck cancer that had progressed within six months of platinum treatment, the first immunotherapy to improve survival in the disease.","summary":"Phase 3 trial of 361 patients with recurrent or metastatic head and neck squamous cell carcinoma progressing within six months of platinum-based therapy, randomised 2:1 to nivolumab or investigator's choice of methotrexate, docetaxel or cetuximab.\n\nMedian overall survival was 7.5 versus 5.1 months (hazard ratio 0.70) and one-year survival 36.0 versus 16.6 percent, with fewer grade 3 to 4 adverse events (13.1 versus 35.1 percent) and better quality of life.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2016","url":"https://doi.org/10.1056/NEJMoa1602252"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/27718784/"}],"tags":[],"related":[],"cancers":["recurrent-metastatic-hnscc","oropharyngeal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-141"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2016,"doi":"10.1056/NEJMoa1602252","pmid":"27718784","authors":"Ferris RL, Blumenschein G, Fayette J, et al.","paperType":"rct","findings":["Median overall survival 7.5 vs 5.1 months; hazard ratio 0.70.","One-year overall survival 36.0 percent vs 16.6 percent."],"whatItMeans":"PD-1 blockade after platinum became standard, and the trial opened the way for first-line pembrolizumab in KEYNOTE-048.","caveats":["Response rate was low (13.3 percent); benefit accrues to a minority of durable responders."],"changedPractice":true,"participants":361},"route":"/key-papers/paper-checkmate-141-ferris-nejm-2016/","neighbours":{"cancer":[{"id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"trial":[{"id":"checkmate-141","kind":"trial","name":"CheckMate 141","route":"/trials/checkmate-141/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}